Spring 2021 CME Symposia

Keynote Symposium and Panel Discussion

FRIDAY, APRIL 16, 2021 · 8:30 – 10:00 AM PACIFIC DAYLIGHT TIME

Call To Action: Addressing The Disproportionate Burden & Disparities with COVID-19

Chaired by: Keith C. Ferdinand, MD

Learning Objectives

After completing this activity, the participant should be better able to:

  • Discuss the disproportionate burden of COVID-19 in racial and ethnic minorities
  • Identify clinical, behavioral, and cultural factors that contribute to the increased COVID-19 burden in racial and ethnic minorities
  • List strategies to decrease the burden of COVID-19, including improving cardiometabolic risk parameters, as well as COVID-19 preventive measures, in individuals from racial and ethnic minorities
  • Recognize common and new misconceptions about COVID-19 vaccines in individuals from racial and ethnic minorities, as well as identify practical steps to improve immunization uptake and access
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Merck Sharp & Dohme Corp.

This activity is approved for AMA PRA Category 1 Credits. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

CME SYMPOSIUM

SATURDAY, APRIL 17, 2021 · 7:30 – 8:30 AM PACIFIC DAYLIGHT TIME

Lipid Management in Very High-Risk Patients Post-MI: Applying Real-World Evidence to Improve Outcomes

Chaired by: Pam R. Taub, MD, FACC

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review current guideline recommendations for lipid testing, lipid targets, and lipid-lowering therapy in patients with a recent MI
  • Interpret the efficacy and safety of PCSK9 inhibitors from clinical trials and RWE studies in ACS patients and their implications for patient selection
  • Develop individualized treatment strategies for very-high risk ASCVD patients with a recent MI that prioritize the early initiation and intensification of treatment to optimize overall outcomes
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. This activity is supported by an educational grant provided by Amgen.

This activity is approved for AMA PRA Category 1 Credits. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

CME SYMPOSIUM

SATURDAY, APRIL 17, 2021 · 12:25 – 1:25 PM PACIFIC DAYLIGHT TIME

Antithrombotic Therapy for Symptomatic PAD: Interpreting the Evidence and Recent Advances

Chaired by: Deepak L. Bhatt, MD, MPH

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiology and major complications of peripheral artery disease and the heightened risk in cardiometabolic patients.
  • Summarize the major findings and implications of trials evaluating the role of direct oral anticoagulants in the management of high-risk patients with stable PAD
  • Discuss recent data about the role of direct oral anticoagulants in patients with PAD who have undergone lower-extremity revascularization
  • Develop individualized strategies for the prevention of adverse cardiovascular and limb events in high-risk cardiometabolic patients with PAD.
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Janssen Scientific Affairs, LLC.

This activity is approved for AMA PRA Category 1 Credits. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

CME GENERAL SESSION

SATURDAY, APRIL 17, 2021 · 4:05 – 4:45 PM PACIFIC DAYLIGHT TIME

Antithrombotic and Antiplatelet Therapy in the Cardiometabolic Patient

Chaired by: Deepak L. Bhatt, MD, MPH

Learning Objectives

After completing this activity, the participant should be better able to:

  • Discuss the impact of diabetes on cardiovascular risk assessment
  • Summarize the results of recently concluded clinical trials about the efficacy and safety of novel antithrombotic approaches in patients with diabetes and concomitant CAD or PAD
CMHC PIM

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Janssen Scientific Affairs, LLC. and AstraZeneca.

This activity is approved for AMA PRA Category 1 Credits. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.